Myeloproliferative disorders and the inherited thrombophilias have been described as the main causes underlying the Budd-Chiari syndrome. Moreover, the presence of the JAK2V617F was associated with a higher frequency of Budd-Chiari syndrome in patients who have overt or even latent myeloproliferative disorder. We herein describe a 28-year-old woman who was diagnosed with Budd-Chiari syndrome and later developed an overt myeloproliferative disorder. The patient was found to carry both the JAK2V617F and the prothrombin G20210A mutation in the heterozygous form. The significance of the chronology of diagnosis is highlighted.
Introduction
Myeloproliferative disorders (MPDs) account for the underlying etiology behind more than half the cases of Budd-Chiari syndrome (BCS). 1 The JAK2V617F is an acquired gain-of-function mutation strongly implicated in the pathogenesis of MPDs. It has been detected in most of patients with polycythemia vera (PV; 65%-97%) and in about half of those with essential thrombocythemia (ET) and idiopathic myelofibrosis. [2] [3] [4] Patients diagnosed with MPD who test positive for JAK2V617F were found to have higher rates of complications such as thrombosis than patients who tested negative for the mutation. 3 Inherited hypercoagulability states such as factor V leiden (FVL) mutation are also a leading cause of BCS. A high prevalence of FVL mutation (26%) has been described in patients with BCS, 5 indicating that patients with this thrombogenic condition have an increased risk for developing the syndrome. The prothrombin G20210A mutation is another inherited thrombophilic risk factor described in patients with BCS. 6 A combination of risk factors is common in patients with BCS, and about 28% of patients have multiple prothrombotic disorders. 1 We herein present a patient who was diagnosed with BCS and later developed ET. The patient was found to carry both the JAK2V617F and the prothrombin G20210A mutation in the heterozygous form.
Case Report
The patient is a 28-year-old woman with an 11-year history of hepatosplenomegaly. Previous investigation with an abdominal computed tomography (CT) scan showed a large, ill-defined, and space occupying lesion completely replacing the right and caudate lobes of the liver. Among its characteristics were cavernous transformation of the portal and the splenic veins. Liver biopsy done at the time showed focal nodular hyperplasia, which was considered a hyperplastic response of the liver parenchyma to a preexisting vascular pathology. Diffuse sinusoidal parenchymal dilatation and venous outflow obstruction were also seen. After 3 years, liver Doppler ultrasound (US) showed evidence of portal vein thrombosis and recanalization with a decreased hepatopetal flow and periportal collaterals. A follow-up Doppler US showed complete occlusion of her portal vein. A diagnosis of BCS was made with severe impingement on blood flow and evidence of portal hypertension. Her direct bilirubin and liver function tests (LFTs) were mildly increased, so was her C-reactive protein (CRP). The complete blood count (CBC) showed a hemoglobin (Hb) level of 12.5 g/dL, a hematocrit (Hct) of 38%, and a platelet count of 250 000/mm 3 . The patient was then managed with oral anticoagulation following which her international normalized ratio (INR) was prolonged (*3) resulting in episodes of bleeding and melena. Her Hb and Hct decreased mildly (11.1 g/dL and 33%, respectively), and she developed grade III gastroesophageal varices that could not be managed with transjugular intrahepatic portosystemic shunt (TIPS) because of high risk. Anticoagulant medication was eventually stopped. Later that year, the patient experienced a rising platelet count (>700 000/mm 3 ). A bone marrow aspirate was done and showed a hypercellular bone marrow with trilaminar hematopoesis, increased megakaryocytes, and active erythropoesis that was slightly dyserythropoetic; thus, confirming the diagnosis of myeloprololiferative essential thrombocytemia as no other cause of thrombocytosis was found. She was started on hydroxyurea with a good response. Recently, the patient was offered a thrombophilia molecular workup including FVL, methylenetetrahydrofolate reductase (MTHFR) C677T, and prothrombin G20210A gene mutations as well as protein C, protein S, antithrombin, lupus anticoagulant, and anticardiolipin antibody serum levels. In addition, she was investigated for JAK2 mutations. The patient was heterozygous for prothrombin G20210A and had a JAK2V617F mutation.
Discussion
The prothrombin G20210A mutation found in our patient, which is associated with increased basal levels of functionally normal prothrombin, is associated with a 3-fold higher risk of thrombosis in heterozygotes than that in the normal healthy population. Homozygosity for the prothrombin gene mutation is much rarer and further increases the risk of thrombosis. 7 Many investigators believe, however, that the G20210A defect alone may not be sufficient for the development of venous thromboembolic events. The estimated risk of thrombosis associated with the prothrombin G20210A mutation was statistically significantly increased only in the subset of patients with additional thrombotic risk factors. 7 Hence, although this mutation has been implicated in the etiology of BCS, it most probably acts to exacerbate the thrombogenic potential of other factors. 5 In the patient described, the JAK2V617F mutation could represent that underlying factor, although mutation analysis was not performed simultaneously at the time of diagnosis of BCS. This mutation has been described in 58% of patients with BCS and in 17% of patients with portal and mesenteric venous thrombosis. 8 However, some of these patients fail to fulfill the accepted diagnostic criteria for MPD. 6 Patel et al 9 found a high prevalence of the JAK2V617F in patients with BCS, none of them previously diagnosed with MPD. Almost a third of these patients developed an overt MPD 1 to 8 years following the diagnosis of BCS. 9 Therefore, it has been suggested that most of the BCS cases without an apparent cause may represent latent forms of MPD. 10 This observation was clearly identified in our patient. Because the JAK2V617F mutation has been shown to be frequently present in patients with BCS, analysis of the mutation should be included in the diagnostic workup, even without the presence of an overt MPD. This is justified by the fact that the presence of the mutation may highlight a latent MPD that renders careful patient follow-up favorable.
